Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East News Digest.
Press releases published on March 13, 2025
TFSF Ventures FZ-LLC Introduces AI-Driven Stablecoin Payment Processing Solutions for High-Risk Industries
EIN Presswire
·
March 13, 2025
Customized Payment Solutions for Businesses Facing High Chargeback Rates and Regulatory Challenges DUBAI, UNITED ARAB EMIRATES, March 13, 2025 /EINPresswire.com/ -- TFSF Ventures FZ-LLC is revolutionizing payment processing for high-risk industries with …
EnnoDC presents positive Phase I data at CROI 2025, demonstrating long-lasting immunity induced by Antibody Mediated Vaccines (AMVs)
GlobeNewswire
·
March 13, 2025
EnnoDC presents positive Phase I data at CROI 2025, demonstrating long-lasting immunity induced by Antibody Mediated Vaccines (AMVs) Findings in HIV highlight AMV technology's versatility, robust immune response, and excellent safety profile, underpinning …
Zeranovia(TM) Weight Loss Product Shows Promising Results in Dosage Trial
GlobeNewswire
·
March 13, 2025
LAS VEGAS, March 13, 2025 (GLOBE NEWSWIRE) -- via IBN -- BioAdaptives Inc. (OTC: BDPT) today announced the successful completion of dosage trials for its innovative weight loss product, Zeranovia™. The trial demonstrated significant weight loss results …
Falcon تطلق برامج للدراسات العليا بالتعاون مع Fujairah Aviation Academy
GlobeNewswire
·
March 13, 2025
دبي، الإمارات العربية المتحدة،, March 13, 2025 (GLOBE NEWSWIRE) -- في خطوة تهدف إلى إعداد الجيل المقبل من القادة وتطوير مهاراتهم، وقّعت شركة Falcon مذكرة تفاهم مع أكاديمية الفجيرة للطيران Fujairah Aviation Academy لإطلاق برامج للدراسات العليا مصمّمة خصيصاً …
Executive Appointments Strengthen Nexxen’s Data, Streaming and Omnichannel Expertise
GlobeNewswire
·
March 13, 2025
NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Nexxen, a global, unified advertising technology platform with deep expertise in data and advanced TV, today announced the appointment of four new executives to spearhead its business development, enterprise …
Salipro Biotech und Boehringer Ingelheim schließen Forschungs- und Lizenzvertrag zur Beschleunigung mehrerer Pipeline-Programme von Boehringer Ingelheim
GlobeNewswire
·
March 13, 2025
STOCKHOLM, March 13, 2025 (GLOBE NEWSWIRE) -- Salipro Biotech AB, ein schwedisches Biotechnologieunternehmen, das sich auf die Stabilisierung anspruchsvoller Wirkstoffziele spezialisiert hat, gab heute einen Forschungs- und Lizenzvertrag mit Boehringer …
Salipro Biotech and Boehringer Ingelheim Enter Research and License Agreement to Accelerate Multiple Boehringer Ingelheim Pipeline Programs
GlobeNewswire
·
March 13, 2025
STOCKHOLM, March 13, 2025 (GLOBE NEWSWIRE) -- Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license agreement with Boehringer Ingelheim to accelerate the …
Salipro Biotech et Boehringer Ingelheim concluent un accord de recherche et de licence en vue d’accélérer plusieurs programmes du pipeline de Boehringer Ingelheim
GlobeNewswire
·
March 13, 2025
STOCKHOLM, 13 mars 2025 (GLOBE NEWSWIRE) -- Salipro Biotech AB, société suédoise de biotechnologie spécialisée dans la stabilisation de cibles pharmacologiques difficiles à étudier, a annoncé ce jour la conclusion d’un accord de recherche et de licence …
Foresight Signs Agreement with Leading Indian Tier-One for Revenue Potential of up to $19.5 Million Between 2025- 2029
GlobeNewswire
·
March 13, 2025
Foresight and Excava, a leading Indian Tier-One Supplier, intend to establish a locally incorporated partnership or joint venture to invest in manufacturing and sales activities in India. Foresight will be responsible for the technology and know-how …
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
GlobeNewswire
·
March 13, 2025
WALTHAM, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, is …
Integral Metals Commences Phase I Exploration at Woods Creek Project in Partnership with Big Rock Exploration
GlobeNewswire
·
March 13, 2025
CALGARY, Alberta, March 13, 2025 (GLOBE NEWSWIRE) -- Integral Metals Corp. (CSE: INTG | OTC: ITGLF | FSE: ZK9) (the “Company” or “Integral”) is pleased to announce the commencement of Phase I exploration on its Woods Creek Project in Montana. The program …
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
GlobeNewswire
·
March 13, 2025
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune® platform candidate targets MUC1-positive solid tumors U.S. Patent #12,201,685 covering methods of using combinations of the …
Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20
GlobeNewswire
·
March 13, 2025
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2024 …
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
GlobeNewswire
·
March 13, 2025
BRISBANE, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Cancer …
MAX Power Retains New Corporate Secretary
GlobeNewswire
·
March 13, 2025
VANCOUVER, British Columbia, March 13, 2025 (GLOBE NEWSWIRE) -- MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; FRANKFURT: 89N) (“MAX Power” or the “Company”) is pleased to announce that it has engaged Ms. Monita Faris as the Company’s new Corporate …
COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product
GlobeNewswire
·
March 13, 2025
No significant clinical adverse event observed in Phase 1clinical study Pharmacokinetic profile established and range of doses selected for Phase 2a Clinical Efficacy Study First patient expected to be treated in the Phase 2a Clinical Efficacy Study on …
Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform
GlobeNewswire
·
March 13, 2025
Raanana, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, previously announced the initiation of …
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
GlobeNewswire
·
March 13, 2025
ASHBURN, Va., March 13, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced recent corporate …
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
GlobeNewswire
·
March 13, 2025
FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) Assuming FDA approval, proposed launch in PSVT targeted for mid-2025 Milestone well-capitalized to commercialize upon …
ProQR Announces Year End 2024 Operating and Financial Results
GlobeNewswire
·
March 13, 2025
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expects up to four clinical data readouts in 2025 and 2026 …